Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Anti-CD47 antibody magrolimab with pembrolizumab in patients with relapsed / refractory classic Hodgkin lymphoma.

Haematologica·2026

Same author

Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotin.

Blood cancer journal·2026

Same author

SAVE, Safe Accelerated Venetoclax Escalation: A phase Ib study of obinutuzumab plus venetoclax with daily ramp-up in CLL.

Blood advances·2026

Same author

A Phase I Study of Copanlisib and Venetoclax in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Clinical lymphoma, myeloma & leukemia·2026

Same author

Impact of novel therapies on the efficacy of posttransplantation brentuximab vedotin maintenance in Hodgkin lymphoma.

Blood advances·2026

Same author

A phase 1/2 study of duvelisib plus venetoclax in patients with relapsed/refractory CLL/SLL or Richter transformation.

Blood advances·2026

Same journal

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Hematology. American Society of Hematology. Education Program·2025

Same journal

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Hematology. American Society of Hematology. Education Program·2025

Same journal

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025

Same journal

Anticoagulants in hematologic malignancies: what is the data?

Hematology. American Society of Hematology. Education Program·2025

Same journal

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025

Same journal

What to know about rare B-cell malignancies in 2025.

Hematology. American Society of Hematology. Education Program·2025

See all related articles

Search research articles

Related Experiment Video

Updated: Mar 29, 2026

Blocking Lymph Flow by Suturing Afferent Lymphatic Vessels in Mice

Blocking Lymph Flow by Suturing Afferent Lymphatic Vessels in Mice

Published on: May 14, 2020

Checkpoint blockade in lymphoma.

Philippe Armand¹

¹Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.

Hematology. American Society of Hematology. Education Program

|December 6, 2015

Summary

This summary is machine-generated.

Immune checkpoint blockade therapy (CBT) revolutionizes cancer treatment by targeting immune evasion pathways. This review explores CBT"s clinical success in lymphoma and projects its future evolution in hematologic malignancies.

More Related Videos

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

Related Experiment Videos

Last Updated: Mar 29, 2026

Blocking Lymph Flow by Suturing Afferent Lymphatic Vessels in Mice

Blocking Lymph Flow by Suturing Afferent Lymphatic Vessels in Mice

Published on: May 14, 2020

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

Area of Science:

Oncology
Immunology
Cancer Therapy

Background:

Tumors evade immune responses by engaging immune regulation pathways.
Immune checkpoint blockade therapy (CBT) utilizes monoclonal antibodies to restore anti-tumor immunity.
Key pathways targeted include cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and programmed-death 1 (PD-1).

Purpose of the Study:

To review current clinical results of CBT in lymphoma.
To discuss the scientific basis of CBT's efficacy in hematologic malignancies.
To project the future evolution of CBT in lymphoma treatment.

Main Methods:

Review of existing clinical trial data on CBT in lymphoma.
Analysis of the immunological mechanisms underlying CBT response.
Synthesis of current findings to forecast future therapeutic developments.

Main Results:

CBT has shown significant therapeutic activity in lymphoma.
The understanding of immune regulation pathways underpins CBT's success.
Lymphoma is a promising area for CBT application in hematologic malignancies.

Conclusions:

CBT has revolutionized solid tumor treatment and shows promise in lymphoma.
Further research into CBT mechanisms and applications in hematologic malignancies is warranted.
The future of CBT in lymphoma involves continued clinical development and exploration of novel strategies.